Cover Image

PAPERBACK
$59.95



View/Hide Left Panel

in developing countries, 488

dietary fiber and, 458, 480

dietary protein and, 457, 458

dose-response assessment for ULs, 483-488

in drinking water, 483

EARs, 24-25, 466, 468, 469, 470, 475, 477, 479

elderly people, 451, 474-475, 479, 559, 562

endogenous losses, 446, 448, 449, 462, 463, 469, 471-473, 476

and enzyme (zinc-dependent) activity, 15, 443, 452-453

in erythrocytes, 442, 451, 452, 453, 473, 482

evidence considered in setting EAR, 463-466, 467-470, 471-475, 476-479

excretion, 446, 448, 463-464, 471-473

exposure assessment, 487

factorial analysis, 15, 442, 447, 462, 463, 467, 468, 469-470, 471-473, 476

factors affecting requirement, 454-458

fasting/starvation and, 446, 448, 451

fetal, 477

finger proteins, 443, 444, 454

folate and, 456

food composition data, 560

food sources, 463, 479, 480

fortified foods, 480, 575

fractional absorption method, 15, 447-448, 449, 450, 462, 463, 468, 469, 472, 473, 474, 476, 478

functions, 15, 44, 108, 442-444

and gastrointestinal distress, 482

gender and, 15, 56-57, 442, 469, 470, 471-472, 473-474, 475, 480-481, 482, 488, 638-641, 652-653, 672-673, 678-679

and gene expression, 15, 442, 443, 454

gene markers of status, 453

and growth velocity, 444, 446-447, 449-450, 452, 454, 462, 464, 465-466, 467-468

in hair, 452, 480

hazard identification, 481-483

and hepatic proteins, 454

and hormone metabolism, 443, 444, 454

in human milk, 6, 51, 457, 460-462, 463, 465, 477-478

and immune function, 443, 444, 447, 449, 453, 474-475, 481, 482, 488

indicators of adequacy, 24-25, 447-454, 488-489

infants, 51, 234, 458-466, 486-487

and infection, 445

intakes, 57, 442, 463, 466, 467, 480-481, 487, 559, 562, 574-575, 638-641, 652-653, 672-673, 678-679

interactions with other nutrients, 108-109, 455-457, 458, 462, 479, 480, 482-483, 506

international comparisons, 476

intestinal losses, 448, 456, 463-464, 472, 476

and iron, 304, 357-358, 373, 455, 458, 482-483

laboratory assays, 452, 471, 474

lactation, 477-479, 487, 488

by life-stage group, 24-25, 27, 458-480, 483-487, 638-641, 652-653, 672-673, 678-679

and lipoproteins, 482

malabsorption syndromes, 445, 446, 457

and Menke’s disease, 488

menstrual losses, 446, 448, 469, 471-472

metabolism, 445-446, 474

metalloenzymes, 443

and metallothionein, 234, 443, 444, 453, 456, 473

method used to set AI, 459, 462

method used to set EAR, 15, 442, 463, 467, 468, 469-470, 476, 572

methodological issues, 452, 476

MTF1 binding, 443

NOAEL/LOAEL, 484-486

and 5'-nucleotidase activity, 453, 473-474

phosphorus and, 455-456, 457

phytic acid/phytates and, 444, 451, 452, 456, 457-458, 479, 480, 572, 576

picolinic acid and, 458

plasma concentrations, 445-446, 447, 450-452, 455, 473, 476, 480

pre-albumin and, 454, 473

pregnancy, 447, 476-477, 487, 488

protein-energy deficiency and, 108

radiotracer studies, 357-358, 455, 472, 489

RDAs, 15, 24-25, 442, 466, 468, 469, 470, 475, 477, 479, 557, 574

regulatory role, 15, 443-444, 454



The National Academies | 500 Fifth St. N.W. | Washington, D.C. 20001
Copyright © National Academy of Sciences. All rights reserved.
Terms of Use and Privacy Statement